Department of Orthopaedics, Case Western Reserve University and Case Medical Center, Cleveland OH 44106, USA.
Curr Mol Pharmacol. 2012 Jun;5(2):127-34.
Intermittent parathyroid hormone (iPTH) is the only FDA-approved therapy for bone loss due to conditions such as osteoporosis that increases bone formation by osteoblasts; all other therapies approved for osteoporosis block bone resorption by osteoclasts. The anabolic effects of iPTH are likely due to a combination of multiple mechanisms, including induction of immediate-early genes, increased expression and/or activity of essential osteoblast transcription factors, and downregulation of anti-osteogenic proteins, such as sclerostin. In contrast, continuous administration of PTH induces bone loss primarily due to up-regulation of RANKL expression and inhibition of osteoprotegerin expression.
间歇甲状旁腺激素（iPTH）是唯一被 FDA 批准用于治疗骨质疏松症等导致骨质流失的药物，它通过成骨细胞增加骨形成；所有其他被批准用于治疗骨质疏松症的药物都通过抑制破骨细胞来阻止骨质吸收。iPTH 的合成代谢作用可能是多种机制共同作用的结果，包括诱导即刻早期基因、增加必需成骨细胞转录因子的表达和/或活性，以及下调抗成骨蛋白，如骨硬化蛋白。相比之下，连续给予 PTH 主要通过上调 RANKL 表达和抑制骨保护素表达来诱导骨质流失。
